A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Public ClinicalTrials.gov record NCT07873931. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-Label Study of BMS-986553, CD19 In Vivo Chimeric Antigen Receptor (CAR) T Cells, in Participants With Refractory Autoimmune Diseases
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).
Study identification
- NCT ID
- NCT07873931
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2026 (Estimated)
- Primary completion
- Oct 20, 2032 (Estimated)
- Completion
- Jan 31, 2033 (Estimated)
- Last update posted
- Oct 14, 2026
2026 – 2033
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0064 | Newport Beach | California | 92663 | — |
| Local Institution - 0001 | Worcester | Massachusetts | 01655 | — |
| Local Institution - 0004 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0013 | Saint Paul | Minnesota | 55108 | — |
| Local Institution - 0062 | Omaha | Nebraska | 68198 | — |
| Local Institution - 0007 | Morristown | New Jersey | 07962 | — |
| Local Institution - 0052 | Great Neck | New York | 11021 | — |
| Local Institution - 0008 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0015 | Salt Lake City | Utah | 84143 | — |
| Local Institution - 0005 | Seattle | Washington | 98104 | — |
| Local Institution - 0003 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07873931, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07873931 live on ClinicalTrials.gov.